Trial · NCT04348136
An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II
NCT04348136, Phase 2, Phase 3, Active not recruiting, JCR Pharmaceuticals Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II. Trials, record NCT04348136. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04348136
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II
- NCT number
- NCT04348136
- Status
- Active not recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 27 participants, actual
- Lead sponsor
- JCR Pharmaceuticals Co., Ltd.
- Conditions
- Mucopolysaccharidosis II
- Interventions
- JR-141
- First posted
- 2020-04-16
- Last updated
- 2026-09-03
Source ClinicalTrials.gov
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Occurrence of adverse events | From the start of study (Week 52 of preceding study) up to the end of study, up to approximately 10.6 years | |
| Primary | Occurrence of adverse reactions | From the start of study (Week 52 of preceding study) up to the end of study, up to approximately 10.6 years | |
| Primary | Incidence of abnormal vital signs | Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years | Laboratory tests (hematology) |
| Primary | Incidence of abnormal vital signs | Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years | Laboratory tests (biochemistry) |
| Primary | Incidence of abnormal vital signs | Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years | Laboratory tests (iron-related tests) |
| Primary | Laboratory tests (urinalysis) | Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years | |
| Primary | Vital signs (pulse rate) | Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years | |
| Primary | Vital signs (body temperature) | Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years | |
| Primary | Vital signs (blood pressure) | Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years | |
| Primary | 12-lead electrocardiogram | Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years | The presence or absence of abnormal findings (if present, specific findings and whether or not they are reported as adverse events) |
1 to 10 of 25Source ClinicalTrials.gov
See all 25 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04348136
GET https://conductscience.org/api/trials/v1/NCT04348136/registered?page=2